Equity Components [Axis]
Preferred Stock [Member]
A P I C Preferred [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stocks [Member]
Retained Earnings [Member]
Related and Nonrelated Parties [Axis]
Investor [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Securities Purchase Agreement [Member]
Class of Stock [Axis]
Series A Convertible Preferred Stock [Member]
Antidilutive Securities [Axis]
Unvested Shares Of Restricted Stock [Member]
Warrant [Member]
Revision of Prior Period [Axis]
Previously Reported [Member]
Income Statement Locations [Axis]
Research and development expenses [Member]
General and administrative expenses [Member]
Laboratory And Patent Maintenance Services [Member]
Counterparty Name [Axis]
HCWG LLC [Member]
Executive Chairman [Member]
Long-Term Debt, Type [Axis]
Convertible Debt [Member]
Sale of Stock [Axis]
Private Placement [Member]
Award Type [Axis]
Product and Service [Axis]
Advisory Services [Member]
Transaction Type [Axis]
Equity Purchase Agreement [Member]
Statistical Measurement [Axis]
Minimum [Member]
Maximum [Member]
Class of Warrant or Right [Axis]
Warrants [Member]
Warrants One [Member]
Warrants Two [Member]
Warrants Three [Member]
Warrants Four [Member]
Warrants Five [Member]
Plan Name [Axis]
2023 Equity Incentive Plan [Member]
Restricted Stock [Member]
Title and Position [Axis]
Chief Executive Officer [Member]
Two Members [Member]
First board members [Member]
Second board members [Member]
Third board members [Member]
Board members [Member]
Five Board Members [Member]
Chief Accounting Officer [Member]
Vesting Activity of Restricted Stock Units [Member]
Line of Credit Agreement [Member]
HCWG [Member]
Orient EuroPharma Co., Ltd. [Member]
Vendor [Member]
IPLSA [Member]
National Institutes of Health [Member]
NIH STTR [Member]
Two Grant [Member]
Subsegments [Axis]
NEO100 [Member]
NEO100-02 [Member]
NEO212 [Member]
NEO216 [Member]
Pediatric [Member]
Laboratory [Member]
Other [Member]
Ms. Shomali [Member]
Individual [Axis]
Yousha Neman-Ebrahim [Member]
Axel Schonthal [Member]
Thomas Chen [Member]
Keithly Garnett [Member]
David Choi [Member]
Jim Delshad [Member]
Ming-Fu Chiang [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
Assets
Current Assets
Cash and cash equivalents
Deferred offering costs
Debt issuance costs – current
Prepaid expenses and other current assets
Prepaid expenses – related parties
Total Current Assets
Non-Current Assets
Debt issuance costs – net of current portion
Right of use asset – operating lease
Intangible assets, net
Other assets
Total Assets
Liabilities and Stockholders’ Deficit
Current Liabilities
Accounts payable
Accounts payable – related parties
Accrued advisory fee – related party
Accrued expenses – related parties
Accrued restricted stock tax withholdings obligations
Accrued expenses and other current liabilities
Litigation settlement payable
Derivative liability – Series A preferred
Convertible promissory notes, net of discount
Lease liability, current
Total Current Liabilities
Long Term Liabilities
Lease liability, net of current portion
Total Liabilities
Commitments and contingencies
Stockholders’ Deficit:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 6,000 shares issued and outstanding as of June 30, 2026 and no shares issued and outstanding as of December 31, 2025
Additional paid in capital - preferred
Common stock, $0.0001 par value, 100,000,000 shares authorized; 25,933,365 and 21,990,688 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
Treasury stock, 1,079,543 shares and 302,766 shares of common stock at June 30, 2026 and December 31, 2025, respectively
Additional paid in capital
Accumulated deficit
Total Stockholders’ Deficit
Total Liabilities and Stockholders’ Deficit
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, common stock
Income Statement [Abstract]
Operating Expenses:
Research and development
Legal and professional
General and administrative
Stock based compensation
Advisory fees
Total Operating Expenses
Loss From Operations
Other Income (Expense):
Interest income
Grant income
Amortization of debt issuance costs
Interest expense
Other income (expense)
Loss on change in fair value of derivative liability related to Series A preferred stock
Gain on change in fair value of derivative liability through equity line of credit
Net Loss
Loss per share:
Basic net loss per share
Diluted net loss per share
Weighted average shares used in computing basic net loss per common share
Weighted average shares used in computing diluted net loss per common share
Statement [Table]
Statement [Line Items]
Beginning balance, value
Beginning balance, shares
Series A preferred shares issued, net of derivative allocation and issuance costs
Series A preferred shares issued, net of derivative allocation and issuance costs, shares
Sale of common stock, net of offering costs
Sale of common stock, net of offering costs, shares
Common stock issued for advisory services
Common stock issued for advisory services, shares
Restricted share grants released from restriction
Restricted share grants released from restriction, shares
Common stock issued for equity line of credit
Common stock issued for equity line of credit, shares
Common stock issued for private placement
Common stock issued for private placement, shares
Warrants issued for private placement
Cashless exercise of warrants
Cashless exercise of warrants, shares
Stock based compensation
Tax effect related to net share settlement of equity awards
Tax effect related to net share settlement of equity awards, shares
Other
Net loss
Ending balance, value
Ending balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of original issue discount on bridge loans - related party
Accretion of original issue discount on convertible promissory note
Amortization of intangible asset - patent
Amortization of right of use asset
Stock based compensation - restricted stock
Gain on change in fair value of derivative liability
Loss on change in fair value of derivative liability related to Series A preferred stock
Transaction costs expensed on issuance of Series A preferred stock
Increase in deferred offering costs
Amortization of debt issuance costs
Changes in operating assets and liabilities:
Prepaid expenses
Other assets
Accrued compensation
Lease liability
Accrued advisory fee
Accounts payable
Accounts payable and accrued expense – related parties
Accrued expense
Net cash used in operating activities
Cash flows from financing activities:
Proceeds from the sale of common stock, net of costs
Proceeds from issuance of common stock and warrants – PIPE financing
Proceeds from related party loan
Repayment of related party loan
Repayment of OID loan
Proceeds from issuance of Series A convertible preferred stock
Payment of issuance costs - Series A Preferred Stock
Proceeds from sale of common stock pursuant to equity purchase agreement
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents - beginning of period
Cash and cash equivalents - end of period
Supplemental cash flow disclosures:
Interest paid on OID loan payment
Interest paid on litigation settlement payment
Supplemental disclosure of non-cash financing activities:
Original issue discount on bridge loan - related party
Financed insurance premiums
Share issued in connection with advisory services
Right of use asset, at lease commencement
Reclassification of deferred offering costs to APIC at the completion of the offering
Accounting Policies [Abstract]
Description of Business and Liquidity and Going Concern
Basis of Presentation and Summary of Significant Accounting Policies
Intangible Asset, Goodwill and Other [Abstract]
Intangible asset – Patent
Related Party Transactions [Abstract]
Related Party Transactions
Related Party Loans Payable
Related Party Loans Payable
Convertible Debt
Convertible Debt
Leases
Leases
Common And Preferred Stock
Common and Preferred Stock
Stock-based Compensation
Stock-Based Compensation
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Grants
Grants
Segment Reporting [Abstract]
Segment Reporting
Subsequent Events [Abstract]
Subsequent Events
Trading Arrangements, by Individual [Table]
Material Terms of Trading Arrangement [Text Block]
Trading Arrangement Adoption Date
Trading Arrangement, Individual Name
Trading Arrangement, Individual Title
Rule 10b5-1 Arrangement Adopted [Flag]
Trading Arrangement Expiration Date
Trading Arrangement, Securities Aggregate Available Amount
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Rule 10b5-1 Arrangement Terminated [Flag]
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Basis of presentation
Principles of consolidation
Use of estimates
Concentrations of Credit Risk and Off-Balance Sheet Risk
Cash and cash equivalents
Deferred offering costs
Debt issuance costs
Intangible Assets
Impairment of Long-Lived Assets
Warrants
Leases
Fair value measurements
Revenue
Research and development
Patent costs
Accounting for Government Grants
Stock-based compensation
Net loss per share
Income taxes
Segment Reporting
Reclassifications
Recent Accounting Pronouncements
Schedule of carrying amount of the Patent
Schedule of amortization expense related to the Patent
Schedule of convertible debt
Schedule of lease liabilities for operating leases
Schedule of assumptions
Schedule of reconciliation of the derivative liability
Schedule of warrants measurement
Schedule of restricted stock units activity
Schedule of segment reporting
Defined Benefit Plan [Table]
Defined Benefit Plan Disclosure [Line Items]
Common stock issued
Proposed sale of common stock
Purchased shares of common stock
Share price
Total commitments
Escrow released
Cash
Net loss
Accumulated deficit
Number of warrants to purchase
Proceeds from common stock and warrants
Proceeds from convertible preferred stock
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Money market funds
Intangible asset
Estimated useful life of intangible assets
Amortization expense
Impairment on Intangible Assets
Impairment of long-lived assets
Revenue
Reduction of research and development expense
Anti-dilutive shares
Current tax provision
Gross carrying value
Accumulated amortization
Net carrying amount
2026 (excluding the six months ended June 30, 2026)
2027
2028
2029
2030
Thereafter
Patent cost
Estimated useful life
Amortization expense
IncomeStatementLocationsAxis [Axis]
Upfront payment
Amendment fees
Advisory fee expense
Advisory fee paid
Monthly installments
Payment of outstanding accrued advisory fee
Diluted shares outstanding
Advisory fee
Accrued advisory fee related party
Nasdaq listing fee
Reimbursable expenses
Reimbursable expenses payable
Annual patent maintenance fee
Royalties percentage
Utilizes laboratory and patent maintenance services
Accrued laboratory and patent maintenance fees payable
Outstanding amounts payable to USC for clinical trial services
Subcontract payable to USC
Accrued compensation
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Due from related party
Advances from related party
Outstanding balance
Interest expense
Advances from related party
Net carrying value as of beginning
Accretion of original issuance discount
Repayment of note
Net carrying value as of ending
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Line Items]
Proceeds from issuance of promissory notes
Principal amount
Debt issuance costs
Interest expense
Accretion of original issuance discount
Amortization of debt issuance costs
2026 (excluding the six months ended June 30, 2026)
2027
2028
2029
2030
Total
Less: interest
Present value of lease liability
Less: current portion
Noncurrent portion
Base rent
Lease increases percentage
Lease discount rate
Operating Lease term
Operating lease liability
Right-of-use asset
Lease liability
Lease expense
Cash paid for amounts included in the measurement of lease liability
Stock Price
Risk-free rate
Equity volatility
Expected Term
Probability of redemption
Probability of conversion
Discount for lack of marketability
Embedded derivative fair value
Balance at initial recognition
Change in fair value recognized in earnings
Balance at ending
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Measurement Date
Stock Price
Risk-Free Rate
Volatility
Expected Term
Warrants issued
Fair Value per Warrant
Aggregate Warrant Fair Value
Common Stock, Shares Authorized
Common Stock, Par or Stated Value Per Share
Preferred Stock, Shares Authorized
Number of common stock
Proceeds from issuance of private placement
Common stock issued for advisory services, shares
Cashless exercise of warrants
Release of restricted stock units
Preferred stock, aggregate stated value
Derivative liability description
Placement fee
Fair value of derivative liability
Change in fair value of derivative liability
Aggregate carrying amount
Proceeds from common stock and warrants
Exercise price
Warrant exercisable term
Private placement description
Total commitments
Placement agent fees
Advisory services fees
Common stock issued for advisory services
Gain on settlement
Value of shares issued
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares of restricted stock, at beginning
Unvested Restricted Stock, at beginning
Unvested Restricted Stock, Granted
Weighted Date Average Grant Fair Value, Granted
Shares of restricted stock, Cancelled
Weighted Date Average Grant Fair Value, Cancelled
Restricted stock units, Forfeited
Weighted Date Average Grant Fair Value, Forfeited
Shares of restricted stock, at ending
Unvested Restricted stock units, Vested
Weighted Date Average Grant Fair Value, Vested
Unvested Restricted Stock, at ending
Stock available for issuance
Restricted stock, granted
Restricted stock, cancelled/ forfeited
Restricted stock, cancelled/ forfeited
Shared based compensation reversal
Stock-based compensation expense
Fair value of restricted stock granted
Unamortized stock-based compensation
Unamortized stock-based compensation, term
Restricted stock units withheld
Treasury stock transaction
Accrued expenses
Accrued interest
Qualitative and Quantitative Information, Transferor's Continuing Involvement [Table]
Qualitative and Quantitative Information, Transferor's Continuing Involvement [Line Items]
Line of credit
Line of credit, interest rate
Expire date
Warrants exercised
Number of shares issuance
Number of shares of common stock remaining available
Fair value of common stock
Expected volatility
Risk-free interest rate
Term
Litigation settlement payable
Accrued interest
Proceeds from grant
Subcontractor costs
Allowable subcontractor
Grant income
Grant receivable
Allowable cost
Segment Reporting [Table]
Segment Reporting [Line Items]
Revenues
Total research and development expense
Advisory fees – related parties
Legal and professional
Employee compensation expenses
Amortization of debt issuance
Investor relations
Stock based compensation
Other general and administrative expense
Loss on change in fair value of derivative liability related to Series A preferred stock
Gain on change in fair value of derivative liability
Other expense
Interest and other income
Number of shares granted
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
AmortizationOfDebtIssuanceCost
Net Income (Loss) Attributable to Parent
Shares, Outstanding
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
GainOnChangeInFairValueOfDerivativeLiability
Derivative, Loss on Derivative
IncreaseInDeferredOfferingCosts
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Other Operating Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Repayments of Related Party Debt
RepaymentOfOidLoan
Payments of Derivative Issuance Costs
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation
RelatedPartyLoansPayableDisclosureTextBlock
ConvertibleDebtTextBlock
LeasesDisclosureTextBlock
GrantsTextBlock
Cash and Cash Equivalents, Policy [Policy Text Block]
DeferredOfferingCostsPoliciesTextBlock
Lessee, Leases [Policy Text Block]
Research and Development Expense, Policy [Policy Text Block]
Segment Reporting, Policy [Policy Text Block]
Revenues [Default Label]
Intangible Asset, Finite-Lived, Accumulated Amortization
Intangible Asset, Finite-Lived, after Accumulated Amortization
Amortization
AccruedCompensation
Convertible Debt [Default Label]
Repayments of Convertible Debt
Long-Term Debt, Gross
Interest Expense, Debt
AccretionOfOriginalIssueDiscount
AmortizationOfDebtIssuanceCosts
Lessee, Operating Lease, Liability, to be Paid, Year One
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
Lessee, Operating Lease, Liability, to be Paid, Year Four
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
Embedded Derivative, Fair Value of Embedded Derivative Liability
CashlessExerciseOfWarrant
ProceedsFromCommonStockAndWarrants
Commitments, Fair Value Disclosure
Stock Issued During Period, Value, Issued for Services
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Settlement Liabilities, Current
Interest Payable, Current
GrantIncome
Legal Fees
ShareBasedCompensations
Litigation Settlement, Loss
Interest and Other Income